Personalized abiraterone or enzalutamide plan for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial compares a personalized (adaptive) treatment plan versus a steady (continuous) plan using either abiraterone or enzalutamide (with the same standard hormone-suppression). It aims to see which approach controls advanced metastatic prostate cancer better while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign consent.
- You have prostate cancer confirmed by biopsy or cell testing, and it has spread to other parts of the body.
- Your testosterone is already kept very low using hormone therapy or surgery, and you’ve been getting worse despite it.
- Your PSA blood level is at least 2, and your cancer symptoms are reasonably controlled.
- You can swallow the study pills and attend required study visits and tests (including sharing tissue or getting a new biopsy).
- You have enough blood counts and healthy enough liver/kidney function for trial treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
This study tests a new form of abiraterone (a hormone therapy) against the standard one in men whose prostate cancer has spread and no longer responds to usual hormone treatment. Participants must have had limited prior treatments and be in decent overall health.
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Hear when a new Prostatic Neoplasms, Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.